TriSalus Life Sciences Inc. (TLSI)
NASDAQ: TLSIHealth CareMedical SpecialitiesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
TLSI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $254.30M
- EPS (TTM)
- -$1.22
- Dividend yield
- None
- 52-week range
- 2.20 – 7.95
- Day range
- 4.02 – 4.14
- Volume / Avg
- 275.54K / 275.38K
- Beta
- —
- Shares outstanding
- 61.57M
52-week range
TLSI stock today
On Oct 8, TLSI ended the session at $4.13, shedding $0.12 (2.82%), versus the S&P 500's 0.47% decline. At this level, TLSI sits in the middle of its 52-week range of $2.20 to $7.95: 48.1% below the high, set on Dec 22, 2025 and 87.7% above the low. TLSI is down 40.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 14.8%.
TriSalus Life Sciences has posted a net loss over the last twelve months (EPS of -$1.22), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About TriSalus Life Sciences
Company profileTriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Ms. Mary T. Szela B.S.N., M.B.A.
- Headquarters
- Westminster, CO
- Employees
- 102
- IPO year
- 2021
- Website
- trisaluslifesci.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$10.40+151.82%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
TriSalus Life Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BDSXBiodesix Inc. | 25.63 | -2.99% | $270.43M | vs TLSI |
| XGNExagen Inc. | 8.17 | -1.57% | $197.92M | vs TLSI |
| BNRBurning Rock Biotech Limited ADR | 15.20 | +0.13% | $160.30M | vs TLSI |
| YDESYD Bio Limited | 5.79 | -1.53% | $410.11M | vs TLSI |
| KEQUKewaunee Scientific Corporation | 33.82 | -0.06% | $97.92M | vs TLSI |
| SERASera Prognostics Inc. Class A | 2.02 | -2.42% | $79.69M | vs TLSI |
| MDXHMDxHealth SA | 0.5805 | -3.22% | $55.39M | vs TLSI |
| ACHAccendra Health Inc. | 0.4432 | -6.28% | $34.08M | vs TLSI |
Indexes, lists and sector
TriSalus Life Sciences stock FAQ
What is TriSalus Life Sciences's stock price today?
TLSI last traded at $4.13 as of Oct 8, 4:00 PM EDT, down 2.82% on the day. Prices are delayed at least 15 minutes.
Who is TriSalus Life Sciences's CEO?
Ms. Mary T. Szela B.S.N., M.B.A. is the chief executive officer of TriSalus Life Sciences Inc., which has about 102 employees.
What is the TLSI 52-week high?
The 52-week high for TLSI is $7.95 and the 52-week low is $2.20. The stock is currently 48.1% below its high.